Wird geladen...
Treating ALK positive lung cancer: Early successes and coming challenges
Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with A...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4142046/ https://ncbi.nlm.nih.gov/pubmed/22473102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2012.43 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|